- Univadis
- 1 comment
ASCO 2017 - Metastatic castration-resistant prostate cancer: indoximod after sipuleucel-T boosts PFSl in phase 2 trial
New role for an IDO pathway inhibitor.
Recommended on Univadis
- Univadis
- 1 comment
ASCO 2017 - Relapsed/refractory diffuse large B-cell lymphoma: JCAR017 achieves high CR rates in phase 1 trial
- Univadis
- no comment
ASCO 2017 - Relapsed/refractory multiple myeloma: LCAR-B38M yields 100% ORR in phase 1 trial
- Univadis
- 1 comment
ASCO 2017 - Melanoma brain mets: nivolumab+ipilimumab deliver promising phase 2 results
- Univadis
- no comment
ASCO 2017 - NHL: 82% ORR with axicabtagene ciloleucel in phase 1/2 ZUMA-1 trial
- Univadis
- 1 comment
ASCO 2017 - High-risk breast cancer: pembrolizumab+standard therapy improved pathologic complete response rates
- Univadis
- 1 comment
ASCO 2017 - Advanced SCLC: promising results with nivolumab±ipilimumab
- Univadis
- 1 comment
ASCO 2017 - Precursor B-cell ALL: 95% CR with autologous T cells genetically targeted to B-cell-specific antigen CD19
- Univadis
- 1 comment
ASCO 2017 - NSCLC: phase 3 study suggests prolonged survival benefit with atezolizumab
Professional Essentials
- Patients Will Be Asking
Is Zika still a threat?
- US Professional News
PCPs: fickle millennials may move on
- US Professional News
Senate health bill includes cuts to Medicaid
- US Professional News
AMA campaign aimed at easy MIPS compliance
- US Professional News
MACRA reporting eased in proposal
- Patients Will Be Asking
Can I get a "gentle" cesarean?
New on Univadis
- Clinical Essentials from Leukemia
- 1 comment
Phase 3 results for darbepoetin alfa in lower-risk MDS with anemia
Meaningful effect on rates of transfusion and erythroid response.
- Clinical Essentials from Eur Urol
- 1 comment
Urological cancers: where do checkpoint inhibitors fit in the treatment paradigm?
Systematic review involves pembrolizumab, nivolumab, and ipilimumab in advanced urothelial, renal, and prostate cancer.
- Clinical Essentials from Ann Surg
- 1 comment
HCC: higher recurrence risk with male liver donors
Association decreases with age.
- Clinical Essentials from Aliment Pharmacol Ther
- no comment
DAAs for HCV: no evidence of HBV reactivation with resolved infection
Data from a large, real-world cohort.
- Clinical Essentials from Contraception
- 1 comment
First trimester surgical abortion: nitrous oxide equal to oral sedation for pain
Nitrous oxide carries the benefit of having no aftereffects, thus not requiring a ride home.
- Clinical Essentials from Int J Rheum Dis
- 1 comment
Anti-CCP antibodies in RA predict carotid plaque
And higher titers predict worse plaque score.
- Clinical Essentials from J Stroke Cerebrovasc Dis
- 1 comment
IVT for stroke: nonintracranial hemorrhage common, but outcomes unaffected
NICH is a common IVT complication, but effects on outcomes were poorly understood.
- Clinical Essentials from Diabetes Care
- 1 comment
OGTT best predicts CAD risk in patients with dysglycemia
A report from EUROASPIRE IV.
- Clinical Essentials from Circulation
- 1 comment
Lower BP targets may yield CV benefits in high-risk patients
Study involving over 31K patients supports BP target below 140/90 mmHg,
- Clinical Essentials from JAMA Oncol
- 1 comment
PPI+capecitabine: worse outcomes in gastroesophageal cancer
Similar to previous findings in CRC.
- Clinical Essentials from N Engl J Med
- 1 comment
Recombinant influenza vaccine offers better protection for seniors
Study of 9003 patients aged 50 and older shows 30% greater efficacy vs inactivated vaccine.
- Clinical Essentials from Cochrane Database Syst Rev
- no comment
Cochrane review: umeclidinium in COPD
A systematic summary of the effectiveness and safety of umeclidinium in COPD.
- Clinical Essentials
- 1 comment
Pediatric celiac disease: new guidelines and web tool for diagnosis
From the Celiac Disease Foundation.
- Clinical Essentials from Breast
- 1 comment
Metastatic breast cancer: CDK4/6 inhibitors are well-tolerated
Results of a meta-analysis of palbociclib and ribociclib.